Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL62 for primary membranous nephropathy (Phase III, China)
CTR20231574Phase 3Active
- Sponsor
- Mabworks Biotech
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Bejescin in idiopathic membranous glomerulonephritis (IMG), sponsored by Mabworks Biotech. Started Jun 2023; status: active.
02
Drugs
Bejescin
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20231574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231574.